Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05900648
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05884320
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
HEALTH4CLL2: a Randomized Waitlist Control Trial of Behavioral Interventions in Patients with Chronic Lymphocytic Leukemia
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05879133
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05879159
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05879120
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05879146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients with Pancreatic Cysts Undergoing Surgical Resection
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05873699
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05866679
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05848843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath